Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis

Figure 5

Meta-analysis of the incidence of neoplasia with placebo versus GLP-1 receptor agonists used.